The bioethical controversy about public policy in the United States regarding human stem cell research, particularly with regard to several potential sources of stem cells, including aborted fetuses, unimplanted embryos following in vitro fertilization (IVF), and embryos created through IVF or cloning for research purposes is examined. On the one hand, the debate about the use of federal funds for this research was not resolved by President Bush’s policy, announced in August 2001, because only a few cell lines are available under this restrictive policy. On the other hand, debate persists about whether the US should adopt a prohibitive, regulatory, or permissive policy toward the deliberate creation of embryos for biomedical research through somatic cell nuclear transfer. Although there is a wide consensus about the need to ban cloning-for-reproduction, there is deep division, reflected in the work of the President’s Council on Bioethics, about a possible ban on cloning-for-biomedical research. The author concludes that ethical controversy will probably persist about both types of policy, and that the policy stalemate will probably also continue, because of fundamental disagreements about the moral status of the early embryo.

Keywords:
Embryo, Ethics, Stem cells
This content is only available via PDF.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.